Medical Oncology

BRCA+   

Questions discussed in this category



Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?


Papers discussed in this category


The New England journal of medicine, 2018-12-27

Lancet Oncol, 2021 Mar 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10

N Engl J Med, 2019 Dec 19

Lancet Oncol, 2015 Jun 23

J Clin Oncol, 2020 Oct 29

N Engl J Med, 2021 Jun 03

N. Engl. J. Med.,

N. Engl. J. Med., 2017 Jun 04

BMC Cancer, 2018 Mar 07

N Engl J Med,

JCO Oncol Pract, 2022 Jan 07

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01

Lancet Oncol, 2020 Aug 27

The Lancet. Oncology, 2018-04

JAMA Oncol,

N. Engl. J. Med.,

The New England journal of medicine, 2018-08-23

Lancet Oncol, 2020 Aug 06

Mol Cell Endocrinol, 2021 Jan 26

The New England journal of medicine, 2018-07-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-10

J. Clin. Oncol., 2020 Sep 20

Annals of Oncology, 2021 Sep 29

J Clin Oncol, 2021 Aug 03

Breast Cancer Res Treat, 2016 Feb 18

Mol Cancer Ther, 2018 Mar 28

Eur J Cancer, 2014 Aug 12